Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395602 · ClinicalTrials.gov registry record · Phase 1
Effect of Cabergoline on Weight and Glucose Tolerance
A Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01395602 is a Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 40 participants.
The verdict
NCT01395602, a Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults. This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks. The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.
Interventions
- OTHER placebo
- DRUG Cabergoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-04 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01395602
The ClinicalTrials.gov registry entry for NCT01395602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01395602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01395602 about?
NCT01395602 is a clinical study titled "Effect of Cabergoline on Weight and Glucose Tolerance". The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults. This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergol...
What is the current status of trial NCT01395602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2002-04. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01395602?
The interventions under investigation include: placebo (OTHER), Cabergoline (DRUG).
Who is sponsoring clinical trial NCT01395602?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.